Sputnik V developers offer AstraZeneca to combine their vaccines

Source : 112 Ukraine

The Russian scientists suppose that the combination of two vaccines will increase the efficacy of the drug
14:18, 27 November 2020

Russian developers of Sputnik V urges the British-Sweden pharmaceutical AstraZeneca Company to combine its vaccine-candidate with the Russian one to increase the efficacy of the drug as Reuters reported.

“If they go for a new clinical trial, we suggest trying a regimen of combining the AZ shot with the #SputnikV human adenoviral vector shot to boost efficacy,” the developers of the Russian vaccine stated.

Related: Belarus to start production of Sputnik-V vaccine already this year, - Healthcare Ministry

Recently, Russia stated that its Sputnik V vaccine has 92% efficacy in the protection of people from Covid-19 according to the interim trials. AstraZeneca reported that its vaccine’s efficiency is 70% and in particular cases, it might reach up to 90%.

Executive Director of AstraZeneca Pascal Soriot reported that the company seems to hold an additional global trial for the estimation of the efficiency of its vaccine after the number of issues that occurred after the last trial.

Related: UNICEF announces the largest, fastest operation on Covid-19 vaccine supply

Besides, AstraZeneca plans to provide up to 200 million doses of its coronavirus vaccine by the end of 2020, and 700 million doses of the substance by the end of the first quarter of 2021.

Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

see more